The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Liyan Xu, MD
- Phone Number: 86-89509157
- Email: xuliyan2009@yahoo.cn
Study Contact Backup
- Name: Jing Liu
- Phone Number: 86-89509157
Study Locations
-
-
-
Beijing, China
- Recruiting
- The Beijing Chest Hospital
-
Contact:
- Liyan Xu, MD
- Email: xuliyan2009@yahoo.cn
-
Principal Investigator:
- Liyan Xu, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent should be obtained before treatment. Patients with good compliance.
- Histologically or cytologically confirmed IIIB/IV NSCLC.
- Progress in the treatment of EGFR TKI.
- Aged from 18 to 75 years (18 and 75 years are included); Gender Not Required.
- ECOG PS 0-1.
- Life expectancy ≥ 3 months.
- At least one measurable lesion (meet the requirements of the standard Response Evaluation Criteria In Solid Tumors (RESCIST) version 1.1). If the lesions that have received local treatment (radiation, radiofrequency, intervention, etc.) are the only lesions, it is required to have clear imaging progress.
Exclusion Criteria:
- Uncontrolled hypertension (systolic ≥140mmHg and/or diastolic ≥90mmHg after medication treatment); Poor control of blood sugar.
- Acute phase of cerebral infarction, or recovery period <2 months.
- A variety of factors that affect the absorption of oral medications (such as inability to swallow, nausea and vomiting, chronic diarrhea, intestinal obstruction, etc.)
- Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions, and fecal occult blood (++); (2) a history of melena and hematemesis within 2 months. Simple fecal occult blood (+) is not an exclusion criterion.
- Coagulation abnormality (INR>1.5×ULN, APTT>1.5×ULN), with bleeding tendency.
- Urine protein ≥ ++ or confirmed 24-hour urine protein quantitation > 1.0 g.
- Pregnant or lactating women.
- Severe liver and kidney dysfunction (grade 4) .
- Allergic to any ingredient of apatinib mesylate.
- A history of abuse of psychotropic substances and are unable to quit smoking or mental disorders.
- According to the investigator's judgment, people with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study.
- Surgery, major trauma or fracture, within 4 weeks before the treatment or unhealed wound before treatment.
- Severe heart disease, such as grade III or above (NYHA standard) congestive heart failure, grade III or above (CCS standard) angina, a history of myocardial infarction within 6 months before the treatment, or medication treated arrhythmia.
- Brain metastasis and meningeal metastasis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Apatinib combined with EGFR-TKI
Apatinib 250 millgram(mg/day(d))combined with EGFR-TKI
|
Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rates (ORR)
Time Frame: two years
|
Objective response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1)
|
two years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate (DCR)
Time Frame: two years
|
Disease Control Rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease according to radiological assessments.
|
two years
|
|
Overall survival (OS)
Time Frame: two years
|
Time from randomization to death for any cause.
|
two years
|
|
Progression free survival (PFS)
Time Frame: two years
|
PFS defined as date of randomization until the date of objectively determined progression defined by Response Evaluation Criteria in Solid Tumors criteria or death from any cause, whichever is first.
|
two years
|
|
Drug safety: Number of participants with treatment-related adverse events
Time Frame: two years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
two years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
Other Study ID Numbers
- BeijingCH002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.